Author

J. C. Melms

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3 Cancer Biology· 2 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 4 Organism:human· 4 Approach:experimental assay· 3 Approach:deep learning· 2 Research Focus:differential expression· 2 Organism:mouse· 2 Assay:scRNA-seq· 2 Approach:statistical model· 2

Frequent Co-Authors

B. Izar· 6 shared C. R. Ager· 2 shared E. M. Mace· 2 shared J. Biermann· 2 shared M. Mu· 2 shared M. Rogava· 2 shared N. Vasan· 2 shared P. Ho· 2 shared

Activity by Year

2019-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

6 shared papersImmunology

B. Izar

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Massively parallel base editing screens to map variant effects on anti-tumor hallmarks of primary human T cells

Z. H. Walsh, P. Shah, N. Kothapalli, G. Nikolenyi, S. Shah, G. Leuzzi, M. Mu, P. Ho, S. Abuzaid, Z. D. Brodtman, N. Vasan, M. N. AlQuaraishi, J. D. Milner, A. Ciccia, J. C. Melms, B. Izar

This study uses base editing to screen for variants affecting T cell anti-tumor functions, identifying mutations that enhance tumor elimination with minimal off-target effects.

bioRxiv · Dec 13, 2023 · PreprintImmunology

Mapping human natural killer cell development in pediatric tonsil by imaging mass cytometry & high-resolution microscopy

E. Hegewisch-Solloa, J. E. Melsen, H. Ravichandran, A. Rendeiro, B. Mundy-Bosse, A. G. Freud, J. C. Melms, S. E. Eisman, B. Izar, E. Grunstein, T. J. Connors, O. Elemento, A. Horowitz, E. M. Mace

This study maps human natural killer cell development in pediatric tonsil using imaging mass cytometry and high-resolution microscopy, revealing stage-specific localization and interactions.

bioRxiv · Sep 5, 2023 · PreprintImmunology

KLRG1 marks tumor-infiltrating CD4 T cell subsets associated with tumor progression and immunotherapy response

C. R. Ager, M. Zhang, M. Chaimowitz, S. Bansal, A. Obradovic, M. Rogava, J. C. Melms, P. McCann, C. Spina, C. G. Drake, M. C. Dallos, B. Izar

The paper identifies KLRG1-expressing CD4 T cell subsets linked to tumor progression and immunotherapy response using longitudinal flow cytometry and machine learning.

bioRxiv · Jan 1, 2023Immunology

The CD58:CD2 axis is co-regulated with PD-L1 via CMTM6 and governs anti-tumor immunity

P. Ho, J. C. Melms, M. Rogava, C. J. Frangieh, S. B. Shah, Z. Walsh, O. Kyrysyuk, A. D. Amin, L. Caprio, B. T. Fullerton, R. Soni, C. R. Ager, J. Biermann, Y. Wang, M. Mu, , B. Izar

The paper identifies the CD58:CD2 axis as co-regulated with PD-L1 via CMTM6 and shows its role in anti-tumor immunity, proposing therapeutic strategies to enhance immunotherapy.

bioRxiv · Mar 21, 2022 · PreprintCancer Biology

Alveolar regeneration following viral infection is independent of tuft cells

J. Que, H. Huang, M. Jiang, Y. Zhang, J. Biermann, J. C. Melms, J. Danielsson, Y. Fang, Y. Yang, L. Qiang, J. Liu, Y. Zhou, M. Wang, Z. Hu, T. Wang, , H. Mou

This study shows that alveolar regeneration after viral infection occurs independently of tuft cells, with ectopic basal progenitor cells generating alveolar epithelial cells through distinct differentiation paths.

bioRxiv · Mar 11, 2022 · PreprintCell Biology

Opposing immune and genetic forces shape oncogenic programs in synovial sarcoma

L. Jerby, C. Neftel, M. E. Shore, M. J. McBride, B. Haas, B. Izar, H. R. Weissman, A. Volorio, G. Boulay, L. Cironi, A. R. Richman, L. C. Broye, J. M. Gurski, C. C. Luo, R. Mylvaganam, , A. Regev

The paper profiles synovial sarcoma tumors to show that the SS18-SSX fusion drives oncogenic programs, which are repressed by immune cells and can be targeted with HDAC and CDK4/6 inhibitors.

bioRxiv · Aug 4, 2019 · PreprintCancer Biology